

SEARCH REQUEST FORM

Requestor's

Name:

L. Brohard &

Serial

Number:

09/127057

Date:

1/26/99

Phone:


308-4719

Art Unit:


4E15

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).



$R = H, C_1 - C_{10}$ unsubst'd. alkyl

$$G = H, Me.$$


A, B = any aryl, heteroaryl ring (opt. subst.)

monocyclic
or
fused

STAFF USE ONLY

Date completed: 1-29-99

Searcher: JOHN DANTZMAN

Terminal time: _____

Elapsed time: .

CPU time: _____

Total time: _____

Number of Searches:

Number of Databases:

Search Site

STIC

✓ CM-1

Pre-S

Type of Search

 N.A. Sequence

 A.A. Sequence

Structure.

Bibliographic

Vendors

IG

STN

Dialog

 APS

Geninfo

 SDC

 DARC/Questel

Other _____

BEST AVAILABLE COPY

=> d his -114

Summary

(FILE 'REGISTRY' ENTERED AT 13:35:10 ON 29 JAN 1999)

DEL HIS Y
L1 STR
L2 0 S L1
L3 SCR 1841 AND 1993
L4 2 S L1 AND L3
L5 269 S L1 AND L3 FUL

FILE 'CAPLUS' ENTERED AT 13:38:31 ON 29 JAN 1999

L6 38 S L5

FILE 'REGISTRY' ENTERED AT 13:38:40 ON 29 JAN 1999

L7 STR L1
L8 0 S L7 SSS SAM SUB=L5
L9 5 S L7 SSS FUL SUB=L5
L10 STR L1
L11 12 S L10 SSS SAM SUB=L5
L12 247 S L10 SSS FUL SUB=L5

FILE 'CAPLUS' ENTERED AT 13:42:13 ON 29 JAN 1999

L13 32 S L12

FILE 'CAOLD' ENTERED AT 13:48:33 ON 29 JAN 1999

L14 4 S L12

FILE 'BEILSTEIN' ENTERED AT 13:49:14 ON 29 JAN 1999

(1 had iteration incomplete)

247 compounds Registry


32 cites Caplus

4 cites Caold

=> d que 113

L1

STR




Parent Search

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 10
GGCAT IS UNS AT 11
GGCAT IS UNS AT 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L3 SCR 1841 AND 1993
L5 269 SEA FILE=REGISTRY SSS FUL L1 AND L3
L10 STR



Subset Search
to Narrow

VAR G1=H/C

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 10
GGCAT IS UNS AT 11
GGCAT IS UNS AT 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L12 247 SEA FILE=REGISTRY SUB=L5 SSS FUL L10
L13 32 SEA FILE=CAPLUS ABB=ON PLU=ON L12

247 compounds
32 sites.

=> d bib abs hitstr



L13 ANSWER 1 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1998:793126 CAPLUS
 DN 130:52434
 TI Prepn. of nitrogenous heterocyclic compounds as hyperlipemia remedies
 IN Ohkura, Naoto; Tsuruoka, Takashi; Usui, Takayuki; Hiraiwa, Yukiko;
 Matsushima, Tetsuya; Shiotani, Masaharu; Niizato, Tetsutaro; Nakatani,
 Yuuko; Suzuki, Shigeki; Kuroda, Chidsuko; Katano, Kiyoaki
 PA Meiji Seika Kaisha, Ltd., Japan; et al.
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9854135 A1 19981203 WO 98-JP2411 19980601

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
 UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI JP 97-141410 19970530
 GI



AB The title compds. [I; A = CR₁R₂(CH₂)_i; (wherein R₁ and R₂ each represents hydrogen or alkyl, i = 0-1), CH:CH, OCH₂, or S(O)_jCH₂ (wherein j = 0-2);
 B = hydrogen or halogen; X = CR₃R₄R₅, NR₆R₇,
 (CH₂CH: C(CH₃)CH₂)_pCH₂CH: C(CH₃)₂
 , alkyl, cycloalkyl, Ph, cinnamyl, or heteroaryl; Y = (CH₂)_q, CH:CH, NR₈,

oxygen, or a bond; Z = carbonyl or a bond; K = alkylene or a bond; L = CH:CH or a bond; and M = hydrogen, alkyl, cycloalkyl, Ph, heterocycle, biphenyl, or diphenylmethyl; p = 0-2; q = 1-6; R3-R5 = hydrogen, phenyl; R6-R7 = hydrogen, Ph, benzyl; R8 = hydrogen, C1-6 alkyl] are prepd. I inhibit the biosynthesis of triglycerides in the liver and also inhibit the secretion of lipoproteins contg. apolipoprotein B from the liver. I are hence useful for the prevention/treatment of hyperlipemia (esp. hyper-VLDL-emia) and diseases caused thereby, such as arteriosclerotic diseases, e.g., myocardial infarct, and pancreatitis. Thus, title compd. (II) was prepd. by multi-step reactions and showed 56% and 90% inhibitory activity for apolipoprotein B and triglycerides. A formulation contg. I was also presented.

IT 217491-47-9P 217491-64-0P 217491-66-2P
217491-67-3P 217491-68-4P 217491-85-5P
217491-87-7P 217491-88-8P 217491-92-4P
217491-93-5P 217491-95-7P 217491-97-9P
217491-99-1P 217492-01-8P 217492-03-0P
217492-06-3P 217492-08-5P 217492-10-9P
217492-13-2P 217492-15-4P 217492-18-7P
217492-20-1P 217492-22-3P 217492-24-5P
217492-26-7P 217492-29-0P 217492-30-3P
217492-31-4P 217492-32-5P 217492-33-6P
217492-34-7P 217492-35-8P 217492-36-9P
217492-42-7P 217492-43-8P 217492-44-9P
217492-45-0P 217492-46-1P 217492-47-2P
217492-48-3P 217492-49-4P 217492-50-7P
217492-51-8P 217492-52-9P 217492-53-0P
217492-55-2P 217492-57-4P 217492-59-6P
217492-61-0P 217492-63-2P 217492-65-4P
217492-67-6P 217492-69-8P 217492-70-1P
217492-71-2P 217492-72-3P 217492-73-4P
217492-74-5P 217492-75-6P 217492-76-7P
217492-77-8P 217492-78-9P 217492-79-0P
217492-80-3P 217492-81-4P 217492-82-5P
217492-83-6P 217492-84-7P 217492-85-8P
217492-86-9P 217492-87-0P 217492-88-1P
217492-90-5P 217492-91-6P 217492-92-7P
217492-93-8P 217492-94-9P 217492-95-0P
217492-96-1P 217492-97-2P 217492-98-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nitrogenous heterocyclic compds. as hyperlipemia remedies)


RN 217491-47-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂

RN 217491-64-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 217491-66-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-67-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-68-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-85-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-87-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-88-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-92-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-93-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-95-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217491-97-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217491-99-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-01-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-03-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-06-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-08-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂




RN 217492-10-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-13-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-15-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-18-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-20-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-22-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-24-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-26-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-29-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-30-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-31-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217492-32-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-33-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




• 2 HCl

RN 217492-34-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● 2 HCl

RN 217492-35-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● 2 HCl


RN 217492-36-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-42-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-43-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-44-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217492-45-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-46-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217492-47-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂



RN 217492-48-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂



RN 217492-49-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂



RN 217492-50-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂



RN 217492-51-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-52-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-53-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-55-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-57-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-59-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 217492-61-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-63-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-65-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-67-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-69-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-70-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-71-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-72-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-73-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-74-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-75-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-76-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-77-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-78-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-79-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-80-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-81-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-82-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217492-83-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-84-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-85-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-86-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-87-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Ph₂CH-CH₂-CH₂




RN 217492-88-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Ph₂CH-CH₂-CH₂




RN 217492-90-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-91-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-92-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 217492-93-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-94-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 217492-95-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-96-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 217492-97-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 217492-98-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




IT 217493-75-9

RL: RCT (Reactant)

(prepn. of nitrogenous heterocyclic compds. as hyperlipemia remedies)

RN 217493-75-9 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



=> d bib abs hitstr 2

L13 ANSWER 2 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1998:126242 CAPLUS
 DN 128:192661
 TI Preparation of pyrimidinylpiperidinylcarbonylpiperazines and related compounds as inhibitors of oxidosqualene cyclase.
 IN Brown, George Robert; Newcombe, Nicholas John; Stokes, Elaine Sophie Elizabeth; Waterson, David
 PA Zeneca Limited, UK; Brown, George Robert; Newcombe, Nicholas John; Stokes, Elaine Sophie Elizabeth; Waterson, David
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806705	A1	19980219	WO 97-GB2029	19970725
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9737017	A1	19980306	AU 97-37017	19970725
PRAI	GB 96-17060		19960814		
	GB 97-3027		19970214		
	WO 97-GB2029		19970725		
OS	MARPAT 128:192661				
GI					



AB Title compds. [I; T1, T3 = N, CR; R = H, alkyl, alkenyl, alkynyl; R1 = H, amino, halo, cyano, alkyl, alkylamino, dialkylamino, alkoxy; m = 1, 2; T2 = CH, N; Q = (substituted) Ph, naphthyl, phenylalkenyl, heteroaryl; Q1 = (CH2)a; Q2 = (CH2)b; Q3 = (CH2)c; Q4 = (CH2)d; X = O, CO, S, SO, SO2,

CH2;

a, b = 2, 3; c, d = 1, 2], were prepd. as antihypercholesteremics. Thus, 4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine in CH2Cl2 was treated with a mixt. of 4-chlorophenylsulfonyl chloride and Et3N in

CH2Cl2

under ice cooling followed by stirring for 18 h at room temp. to give 26% 1-(4-chlorophenylsulfonyl)-4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine. The latter at 5 mg/kg orally in rats gave 72%

inhibition of cholesterol biosynthesis.


IT 203523-00-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrimidinylpiperidinylcarbonylpiperazines and related compds. as inhibitors of oxidosqualene cyclase)

RN 203523-00-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-methyl-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 3

L13 ANSWER 3 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1998:28740 CAPLUS
DN 128:88669
TI Preparation of diaryl antimicrobial agents
IN Kanojia, Ramesh M.; Demers, James P.; Hlasta, Dennis J.; Johnson, Sigmond G.; Klaubert, Dieter H.
PA Ortho Pharmaceutical Corp., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9748674	A1	19971224	WO 97-US9955	19970606
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN			
	RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,			
SE	US 5773469	A	19980630	US 96-665653	19960618
	AU 9734804	A1	19980107	AU 97-34804	19970606
PRAI	US 96-665653		19960618		
	WO 97-US9955		19970606		
OS	MARPAT 128:88669				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; L = N, CH, C; G, E = (un) substituted Ph, phenylC1-4alkyl, 2-pyridyl, etc.; G and E together with L (when L = CH) = II, III; J = CH, O; q = 0-1; m = 0-6; X = O, S, NH, etc.; Ar = (un)substituted Ph, biphenyl, naphthyl; p = 0-1; W = O, S; n = 0-6; A = NR1R2, N+R1R2R3*Z-, NR1C(:NR2)NHR3, etc. (wherein R1-R3 = H, C1-6 alkyl, phenylC1-6alkyl; Z = pharmaceutically acceptable counterion)] and their salts, useful in treating bacterial infections, were prepd. Thus, treatment of tyramine with di-tert-Bu dicarbonate in THF followed by reacting the resulting N-(tert-butoxycarbonyl)-2-(4-hydroxyphenyl)ethylamine with 3,3-diphenylpropanol in the presence of di-Et azodicarboxylate, triphenylphosphine in THF, and deprotection of the resulting N-(tert-butoxycarbonyl)-2-[4-(3,3-diphenylpropoxy)phenyl]ethylamine with HCl/IPA afforded the title compd. IV.HCl which showed IC50 of 31.25 .mu.M against histidine protein kinase (HPK) in vitro assay.

IT 201043-63-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of diaryl antimicrobial agents)

RN 201043-63-2 CAPLUS


CN Piperazine, 1-[4-(3,3-diphenylpropoxy)phenyl]-4-(3,3-diphenylpropyl)-(9CI) (CA INDEX NAME)



=> d bib abs hitstr 4

L13 ANSWER 4 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1997:776083 CAPLUS
 DN 128:34785
 TI Preparation of 2-(piperazinoalkylamino)benzoxazoles and -thiazoles as
 dopamine D4 antagonists
 IN Kennis, Ludo Edmond Josephine; Mertens, Josephus Carolus; Pieters, Serg
 Maria Aloysius
 PA Belg.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9743271	A1	19971120	WO 97-EP2505	19970502
	W:	AL, AM, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN			
	RW:	GE, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9729560	A1	19971205	AU 97-29560	19970502
PRAI	EP 96-201282		19960510		
	WO 97-EP2505		19970502		
OS	MARPAT 128:34785				
GI					



~~AB Title compds. [I; R = NR₂(CH₂)_nZ₁R₃; Z₁ = piperazine-1,4-diyl][II; R₁ = H,~~

~~halo, alkyl, alkoxy; R₂ = H, (phenyl)alkyl, Ph, Bz; R₃ = (un)substituted Ph or naphthyl; Z = O or S; n = 2-5] were prepd. Thus, 1-(3,4-dichlorophenyl)piperazine was N-alkylated by Cl(CH₂)₄CN and the hydrogenated product condensed with 2-chlorobenzothiazole to give II (R₁~~

~~= R₂ = H, R₃ = C₆H₃Cl₂-3,4, Z = S, n = 5). Data for biol. activity of II were given.~~

IT 199616-61-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 2-(piperazinoalkylamino)benzoxazoles and -thiazoles as dopamine D4 antagonists)


RN 199616-61-0 CAPLUS

CN 2-Benzothiazolamine, N-[2-[4-(3,4-dichlorophenyl)-1-piperazinyl]ethyl]-N-phenyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 199616-60-9

CMF C25 H24 Cl2 N4 S

*homolog.*


CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.



=> d bib abs hitstr 5

L13 ANSWER 5 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1997:687574 CAPLUS
DN 128:128
TI Structure-activity relationship studies of CNS agents. Part 32. Effect of structural modifications in 1-arylpiperazine derivatives on .alpha.1-adrenoreceptor affinity
AU Mokrosz, Maria J.; Paluchowska, Maria H.; Charakchieva-Minol, Sijka; Bien, Anna
CS Institute Pharmacology, Polish Academy Sciences, Krakow, 31343, Pol.
SO Arch. Pharm. (Weinheim, Ger.) (1997), 330(6), 177-180
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH
DT Journal
LA English
AB The .alpha.1-adrenergic and 5-HT1A serotonergic receptor affinities of a series of 1-arylpiperazines are presented. The role of the spacer and the influence of the terminal substituents on the .alpha.1-adrenoreceptor affinity and the 5-HT1A/.alpha.1 receptor selectivity are discussed.
IT 171415-34-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structural modifications in 1-arylpiperazine derivs. effect on .alpha.1-adrenoreceptor affinity)
RN 171415-34-2 CAPLUS
CN 1H-Benzotriazole,
1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]-1-phenylpropyl]-
(9CI) (CA INDEX NAME)



=> d bib abs hitstr 6

L13 ANSWER 6 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1997:588612 CAPLUS

DN 127:257915

TI Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea pig and human 5-HT auto- and heteroreceptors

AU Schlicker, E.; Fink, K.; Molderings, G. J.; Price, G. W.; Duckworth, M.; Gaster, L.; Middlemiss, D. N.; Zentner, J.; Likungu, J.; Gothert, M.

CS Institut Pharmakologie Toxikologie, Universitat Bonn, Bonn, D-53113, Germany

SO Naunyn-Schmiedeberg's Arch. Pharmacol. (1997), 356(3), 321-327
CODEN: NSAPCC; ISSN: 0028-1298

PB Springer

DT Journal

LA English

AB Human cerebral cortical slices and synaptosomes, guinea-pig cerebral cortical slices and human right atrial appendages were used to study the effects of SB-216641, a preferential h5-HT1B receptor ligand, and of BRL-15572, a preferential h5-HT1D receptor ligand, on the presynaptic h5-HT1B and h5-HT1B-like autoreceptors in the human and guinea-pig brain preps., resp., and on the presynaptic h5-HT1D heteroreceptors in the human atrium. The brain preps., preincubated with [3H]serotonin ([3H]-5-HT), and the segments of atrial appendages, preincubated with [3H]noradrenaline, were superfused with modified Krebs' soln. and tritium overflow was evoked elec. (human and guinea-pig cerebral cortex slices

and

human atrial appendages) or by high K⁺ (human cerebral cortex synaptosomes). The elec. evoked tritium overflow from guinea-pig

cerebral

cortex slices was reduced by the 5-HT receptor agonist 5-carboxamidotryptamine (5-CT). This effect was not modified by

BRL-15572

(2 .mu.M; concn. 154 times higher than its K_i at h5-HT1D receptors) but was antagonized by SB-216641 (0.1 .mu.M; concn. 100 times higher than its K_i at h5-HT1B receptors; apparent pA₂ 8.45). SB-216641 (0.1 .mu.M) by itself facilitated, whereas BRL-15572 (.mu.M) did not affect, the evoked overflow. In human cerebral cortex slices SB-216641 (0.1 .mu.M) also facilitated, and BRL-15572 (2 .mu.M) again failed to affect, the elec. evoked tritium overflow. In human cerebral cortical synaptosomes, 5-CT reduced the K⁺-evoked tritium overflow. This response was unaffected by BRL-15572 (300 nM) but antagonized by SB-216641 (15 nM; drug concns. 23 and 15 times higher than their K_i at h5-HT1D and h5-HT1B receptors, resp.). Both drugs, given alone, did not modify the K⁺-evoked tritium overflow. In human atrial appendages, the elec. evoked tritium overflow was inhibited by 5-HT in a manner susceptible to antagonism by BRL-15572 (300 nM; 23 times K_i at h5-HT1D receptors) but not by SB-216641 (30 nM;

30

times K_i at h5-HT1B receptors). Both drugs by themselves did not change the elec. evoked tritium overflow. In conclusion, SB-216641 behaves as a preferential antagonist at native human 5-HT1B receptors and BRL-15572 as a preferential antagonist at native human 5-HT1D receptors. These

comps.

are clearly useful tools for the differentiation between human 5-HT1B and 5-HT1D receptors in functional studies.

IT 193611-72-2, BRL-15572

RL: BAC (Biological activity or effector, except adverse); BIOL

order via ILL


(Biological study)

(effects of selective 5-HT receptor ligands SB-216641 and BRL-15572 on guinea pig and human 5-HT auto- and heteroreceptors)

RN 193611-72-2 CAPLUS

CN 1-Piperazineethanol, 4-(3-chlorophenyl)-.alpha.-(diphenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

on
wrong
carbon! ↓



● 2 HCl

~~102~~
Same compd
as in DNS, 8!

=> d bib abs hitstr 7

L13 ANSWER 7 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1997:588602 CAPLUS

DN 127:257483

TI SB-216641 and BRL-15572-compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors

AU Price, G. W.; Burton, M. J.; Collin, L. J.; Duckworth, M.; Gaster, L.; Gothert, M.; Jones, B. J.; Roberts, C.; Watson, J. M.; Middlemiss, D. N.

CS Dep. Neuroscience, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19

5AW, UK

SO Naunyn-Schmiedeberg's Arch. Pharmacol. (1997), 356(3), 312-320

CODEN: NSAPCC; ISSN: 0028-1298

PB Springer

DT Journal

LA English

AB Despite only modest homol. between h5-HT1B and h5-HT1D receptor amino acid

sequences, these receptors display a remarkably similar pharmacol. To date there are few compds. which discriminate between these receptor subtypes and those with some degree of selectivity, such as ketanserin, have greater affinity for other 5-HT receptor subtypes. We now report on two compds., SB-216641 (N-[3-(2-dimethylamino)ethoxy-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-carboxamide) and BRL-15572 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol, which display high affinity and selectivity for h5-HT1B and h5-HT1D receptors, resp. In receptor binding studies on human receptors expressed in CHO cells, SB-216641 has high affinity (pKi = 9.0) for h5-HT1B receptors and has 25-fold lower affinity at h5-HT1D receptors.

In contrast, BRL-15572 has 60-fold higher affinity for h5-HT1D (pKi = 7.9) than 5-HT1B receptors. Similar affinities for these compds. were detd.

on native tissue 5-HT1B receptors in guinea-pig striatum. Functional activities of SB-216641 and BRL-15572 were measured in a

[35S]GTP-.gamma.S

binding assay and in a cAMP accumulation assay on recombinant h5-HT1B and h5-HT1D receptors. Both compds. were partial agonists in these high receptor expression systems, with potencies and selectivities which correlated with their receptor binding affinities. In the cAMP accumulation assay, results from pKB measurements on the compds. again correlated with receptor binding affinities (SB-216641, pKB = 9.3 and

7.3;

BRL-15572, pKB = <6 and 7.1, for h5-HT1B and h5-HT1D receptors resp.). These compds. will be useful pharmacol. agents to characterize 5-HT1B and 5-HT1D receptor mediated responses.


IT 193611-72-2, BRL-15572

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(SB-216641 and BRL-15572 pharmacol. discriminate h5-HT1B and h5-HT1D receptors)

RN 193611-72-2 CAPLUS

CN 1-Piperazineethanol, 4-(3-chlorophenyl)-.alpha.-(diphenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

Same Comp
Lesson #8

=> d bib abs hitstr 8

L13 ANSWER 8 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1997:453144 CAPLUS

DN 127:156586

TI Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig

AU Hagan, Jim J.; Slade, Paula D.; Gaster, Laramie; Jeffrey, Phillip;
Hatcher, Jonathan P.; Middlemiss, D. N.

CS Neuroscience Research, SmithKline Beecham Pharmaceuticals, New Frontiers
Science Park North, Third Avenue, Harlow Essex, CM19 5AW, UK

SO Eur. J. Pharmacol. (1997); 331(2/3), 169-174

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier

DT Journal

LA English

AB The selective, brain penetrant, 5-HT1B/D (formerly 5-HT1D.beta./alpha.)
receptor agonist SKF-99101H (3-(2-dimethylaminoethyl)-4-chloro-5-
propoxyindole hemifumarate) (30 mg/kg i.p.) causes a dose related fall in
rectal temp. in guinea pigs which previous studies have shown to be
blocked by the non-selective 5-HT1B/D receptor antagonist GR-127935
(N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4'-(5-methyl-
1,2,4-oxadiazol-3-yl) [1,1'-biphenyl]-4-carboxamide oxalate). The present
study shows that the hypothermic response to SKF-99101H is
dose-dependently blocked by SB-224289G (1'-methyl-5-(2'-methyl-4'-[(5-
methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl)-2,3,6,7-
tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidone] hemioxalate) (0.3-10.0
mg/kg p.o.) (ED50 3.62 mg/kg), which is the first compd. to be described
which is more than 60 fold selective for the 5-HT1B receptor over the
5-HT1D receptor. SB-216641A (N-[3-(2-dimethylamino) ethoxy-4-methoxy-
phenyl] 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-
carboxamide hydrochloride) (0.6-20.0 mg/kg i.p.), which is somewhat less
selective (30 fold) for the 5-HT1B receptor over the 5-HT1D receptor had

a

similar effect (ED50 4.43 mg/kg). The brain penetrant 5-HT1D selective
receptor antagonist, BRL-15572 (4-(3-chlorophenyl)-.alpha.-
(diphenylmethyl)-1-piperazineethanol dihydrochloride) (0.3-100.0 mg/kg
i.p.) was inactive. When administered alone neither BRL-15572 (0.1-10
mg/kg i.p.) nor SB-224289G (2.2-22 mg/kg p.o.) had an effect on body

temp

These data demonstrate that 5-HT1B (formerly 5-HT1D.beta.) and not 5-HT1D
(formerly 5-HT1D.alpha.) receptors mediate the hypothermic response to
SKF-99101H (30 mg/kg i.p.) in guinea pigs. The compds. described are
useful pharmacol. tools for distinguishing responses to 5-HT1B and 5-HT1D
receptors.

IT 193611-72-2, BRL 15572

RL: BAC (Biological activity or effector, except adverse); BPR


(Biological

process); BIOL (Biological study); PROC (Process)

(pharmacol. tools for distinguishing responses to 5-HT1B and 5-HT1D
receptors)

RN 193611-72-2 CAPLUS

CN 1-Piperazineethanol, 4-(3-chlorophenyl)-.alpha.-(diphenylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



• 2 HCl

OK
on Wrong


Carbon

✓ ~~For~~

=> d bib abs hitstr 9

L13 ANSWER 9 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1996:567069 CAPLUS
DN 125:221856
TI Preparation of quinazoline derivatives as adrenergic .alpha.1C receptor antagonists
IN Andrews, Robert Carl; Brown, Peter Jonathan; Deaton, David Norman; Drewry, David Harold; Foley, Michael Andrew; Garrison, Deanna T.; Marron, Brian Edward; Smalley, Terrence L.; Berman, Judd M.; Noble, Stewart Alywyn
PA Glaxo Inc, USA
SO Brit. UK Pat. Appl., 190 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2295387	A1	19960529	GB 94-23635	19941123
OS	MARPAT 125:221856				
GI					



AB Title compds. [I; R = Z1Z2 = R4; R1 = H, halo, alkyl, alkoxy, etc.; R4 = H, (di)(alkyl)amino, phenyl(oxy), etc.; R5,R6 = H, OH, halo, alkyl, alkoxy; Z1 = NH, 2-(piperazine-1,4-diyl)ethylimino, iminopyridine-5,2-diylimino, etc.; Z2 = bond, (un)substituted alkylene] were prepd. as adrenergic .alpha.1C receptor antagonists (no data). Thus, 4-chloro-2-phenylquinazoline was aminated by 4-amino-1-benzylpiperidine and the deprotected product N-alkylated by 5-(2-chloroethyl)-2-methoxybenzenesulfonamide (prepn. given) to give title compd. II.

IT 181114-29-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazoline derivs. as adrenergic .alpha.1C receptor antagonists)

RN 181114-29-4 CAPLUS
CN Quinazoline, 4-[4-(3,3-diphenylpropyl)-1-piperazinyl]-2-phenyl- (9CI)
(CA INDEX NAME)



excluded


4; $p+q = 0$ to 4, wherein p is 0, 1 or 2 and q is 0 or 1; and w , x , y and z represent each an integer of 0 to 2, and $w+x+y+z = 1$ or 2, provided when $R1$ to $R4$ represent each a specifically limited group, $w+x+y+z$ may be 0] are prepd. 2-[3-(4-Phenoxypiperidino)propyl]-2H-1,2-benzothiazin-4(3H)-one 1,1-dioxide hydrochloride (II) was prepd. in several steps starting from 2H-1,2-benzothiazin-4(3H)-one 1,1-dioxide ethylene ketal. II at 1 mg/kg i. v. inhibited urinary bladder contractions in rats.

IT 173365-96-3p

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzothiazine derivs. for inhibiting dysuria)

RN 173365-96-3 CAPLUS

CN 1,2-Benzisothiazol-3(2H)-one, 2-[1-phenyl-3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

=> d bib abs hitstr 11

L13 ANSWER 11 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1995:995626 CAPLUS
 DN 124:145926
 TI Preparation of aminoalkylisochromans, -isoquinolines, and related compounds as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors.
 IN Kato, Kaneyoshi; Sugiura, Yoshihiro; Kato, Koichi; Nagai, Yasuo
 PA Takeda Chemical Industries, Ltd., Japan
 SO Eur. Pat. Appl., 104 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 679642	A1	19951102	EP 95-106189	19950426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5607939	A	19970304	US 95-428499	19950425
	CA 2148047	AA	19951029	CA 95-2148047	19950427
	JP 08012650	A2	19960116	JP 95-103389	19950427
	US 5654296	A	19970805	US 96-760904	19961206
PRAI	JP 94-114054		19940428		
	JP 94-92769		19940428		
	US 95-428499		19950425		
OS	MARPAT 124:145926				
GI					



AB Title compds. (I; Ar = arom. group; R1, R2, R3 = H, acyl, hydrocarbyl; R1R2N = heterocyclyl; m = 1-6; n = 2, 3; dotted line = optional double bond; X = O, NR3, N:), were prepd. Thus, 4-(2-iodoethyl)-4-phenylisochroman and imidazole were stirred with K2CO3 in MeCN for 4 days at 60.degree. to give 4-phenyl-4-[2-(1-imidazolyl)ethyl]isochroman, isolated as the hydrochloride. I inhibited 5-HT uptake in rat brain preps. with IC50 = 0.03-1.0 .mu.M. I drug formulations are given.

IT 173272-96-3
 RL: RCT (Reactant)
 (prepn. of aminoalkylisochromans, -isoquinolines, and related compds. as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors)

RN 173272-96-3 CAPLUS
 CN Formamide, N-[4-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylbutyl]- (9CI) (CA INDEX NAME)




IT 173272-74-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aminoalkylisochromans, -isoquinolines, and related compds.
as gonadotropin-releasing hormone antagonists, calcium antagonists,
and/or monoamine uptake inhibitors)

RN 173272-74-7 CAPLUS

CN Formamide, N-[4-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylbutyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

=> d bib abs hitstr 12

L13 ANSWER 12 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1995:801125 CAPLUS

DN 124:8755

TI Structure-activity relationship studies of CNS agents. Part 22. A search for new trazodone-like antidepressants: synthesis and preliminary receptor

binding studies

AU Mokrosz, Jerzy L.; Duszynska, Beata; Paluchowska, Maria H.; Charakchieva-Minol, S.; Mokrosz, Maria J.

CS Institute Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.

SO Arch. Pharm. (Weinheim, Ger.) (1995), 328(7-8), 623-5

CODEN: ARPMAS; ISSN: 0365-6233

DT Journal

LA English

AB New 1-phenyl- and 1-(3-chlorophenyl)piperazines contg. a 4-[3-(heterocyclic)propyl] fragment were synthesized. Several derivs. were selected as good candidates for new, potential antidepressants on

the

basis of their 5-HT1A/5-HT2A receptor binding profiles.

IT 171112-91-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and 5-HT1A/5-HT2A receptor binding profiles of (heterocyclylpropyl)-substituted piperazines)

RN 171112-91-7 CAPLUS

CN 1H-Benzotriazole,

1-[3-[4-(3-chlorophenyl)-1-piperazinyl]-1-phenylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)



=> d bib abs hitstr 13

L13 ANSWER 13 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1995:801121 CAPLUS
DN 124:8013
TI Structure-activity relationship studies of CNS agents. Part 23.
N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-tetrahydroisoquinoline
mimic 1-phenylpiperazine at 5-HT1A receptors
AU Mokrosz, Jerzy L.; Bojarski, Andrzej J.; Charakchieva-Minol, Sijka;
Duszynska, Beata; Mokrosz, Maria J.; Paluchowska, Maria H.
CS Institute Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.
SO Arch. Pharm. (Weinheim, Ger.) (1995), 328(7-8), 604-8
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA English
OS CASREACT 124:8013
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The 5-HT1A receptor affinities and ionization consts. of a set of
1-arylpiperazine, 1,2,3,4-tetrahydroisoquinoline, and -quinoline contg.
N-(.omega.-arylalkyl) or N-(E)-cinnamyl substituents as well as two
morpholine derivs. (I, II) were detd. It was shown that some
tetrahydroisoquinoline (III, IV) and morpholine (I) derivs. were 5-HT1A
ligands equipotent to 1-phenylpiperazine (V) and 1,2,3,4,4a,5-
hexahydropyrazino[1,2-a]indole (VI). On the basis of mol. modeling
studies it was also demonstrated that III, IV and I mimicked very well
the
ref. structures of V and its rigid analog VI. Another, more complex
1,2,3,4-tetrahydroisoquinoline deriv. VII, which served as a model compd.
to confirm the previously reported 5-HT1A binding mode of other
1-phenyl-1,2,3,4-tetrahydroisoquinolinone derivs., had the highest 5-HT1A
affinity ($K_i = 6.7 \pm 0.5$ nM) of all the investigated compds.


IT 171415-34-2P

RL: GPN (Synthetic preparation); PREP (Preparation)
(QSAR of CNS agents N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-
tetrahydroisoquinoline as 1-phenylpiperazine mimics at 5-HT1A
receptors)

RN 171415-34-2 CAPLUS

CN 1H-Benzotriazole,

1-[3-[4-(2-methoxyphenyl)-1-piperazinyl]-1-phenylpropyl]-
(9CI) (CA INDEX NAME)



BERNHARDT

09/127059

Page 22




=> d bib abs hitstr 14

L13 ANSWER 14 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1992:490321 CAPLUS
 DN 117:90321
 TI Piperazine derivatives
 IN Ward, Terence James; Warrellow, Graham John
 PA John Wyeth and Brother Ltd., UK
 SO Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 479546	A2	19920408	EP 91-308969	19911001
	EP 479546	A3	19920603		
	EP 479546	B1	19961030		
	R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE				
	AU 9184883	A1	19920409	AU 91-84883	19910930
	AU 642532	B2	19931021		
	US 5177078	A	19930105	US 91-768147	19910930
	GB 2248616	A1	19920415	GB 91-20856	19911001
	GB 2248616	B2	19940615		
	JP 04257570	A2	19920911	JP 91-253585	19911001
	AT 144772	E	19961115	AT 91-308969	19911001
	ES 2094204	T3	19970116	ES 91-308969	19911001
	CA 2052619	AA	19920404	CA 91-2052619	19911002
	HU 59394	A2	19920528	HU 91-3160	19911003
PRAI	GB 90-21453		19901003		
OS	MARPAT 117:90321				
GI					


Applied.



AB Piperazines I (X = alkylene; R = H, alkyl; R1, R4 = aryl, heteroaryl; R2 = mono- or bicyclic heterocyclic; R3 = H, OH, alkyl) were prep'd. Thus, 1-(2-methoxyphenyl)piperazine was treated with styrene oxide followed by imidazole to give the piperazine II. II had 5-hydroxytryptamine type 1A receptor antagonist activity in rats at a min. ED of 1 mg/kg s.c. and 10 mg/kg orally.

IT 141733-62-2P 141733-71-3P 142234-34-2P
 142234-35-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)


RN 141733-62-2 CAPLUS
 CN Piperazine, 1-[3-(1H-imidazol-1-yl)-3-phenylpropyl]-4-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)



excluded


RN 141733-71-3 CAPLUS

CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phenylpropyl]- (9CI) (CA INDEX NAME)




RN 142234-34-2 CAPLUS

CN Piperazine, 1-[3-(1H-imidazol-1-yl)-3-phenylpropyl]-4-(2-methoxyphenyl)-, trihydrobromide (9CI) (CA INDEX NAME)




RN 142234-35-3 CAPLUS

CN Piperazine, 1-(2-methoxyphenyl)-4-[3-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phenylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)



=> d bib abs hitstr 15

L13 ANSWER 15 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1992:426513 CAPLUS
DN 117:26513
TI New triazine derivatives as potent modulators of multidrug resistance
AU Dhainaut, Alain; Regnier, Gilbert; Atassi, Ghanem; Pierre, Alain; Leonce, Stephane; Kraus-Berthier, Laurence; Prost, Jean Francois
CS Inst. Rech. Servier, Suresnes, 92150, Fr.
SO J. Med. Chem. (1992), 35(13), 2481-96
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CJACS
GI



AB 70 Triazines, e.g., I (X = bond, NH, aminoalkylene; Y = N; R = diarylalkyl, dibenzocycloheptenyl, dibenzoheteroaryl) were prepd. from chlorotriazines and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compds., I [X = bond, Y = CH, R = NHCH2CH(C6H4F-4)2] (II) (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5 .mu.M in DC-3F/AD and KB-A1 cells, resp.) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compds. and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the Pgp-catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in assocn. with the antitumor drug vincristine (0.25 mg/kg), II (100 mg/kg) increased the T/C by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, II was selected for a clin. development because it was more bioavailable than I [X = bond, Y = CH, R = (dibenzo[a,d]cyclohepten-5-ylmethyl)amino], even though it was less active.

IT 27469-55-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as modulator for multidrug resistance)


RN 27469-55-2 CAPLUS
CN 1,3,5-Triazine-2,4-diamine,
6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-N,N'-
di-2-propenyl- (9CI) (CA INDEX NAME)

excluded

BERNHARDT


09/127059

Page 27




=> d bib abs hitstr 16

L13 ANSWER 16 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1981:586978 CAPLUS
DN 95:186978
TI Synthesis of geminal 3,3-dithienyl compounds
AU Kleemann, A.; Heese, J.; Engel, J.
CS Pharmaforsch. Chemiewerk Homburg, Zweigniederlassung Degussa,
Frankfurt/Main, Fed. Rep. Ger.
SO Arzneimittel.-Forsch. (1981), 31(8), 1178-83
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German
AB (R)-(+)-R₂C:CHCH₂NHCHMeCHPhOH (I; tinofedrine; R = 3-thienyl throughout)
was prepd. by the reaction of RLi with BrCH₂CH₂CO₂Et to give 96%
HOCH₂CH₂CH₂Br (II), which reacted with (-)-norephedrine to give 69%
HOCH₂CH₂CH₂NHCHMeCHPhOH.HCl, which was dehydrated by HCl in EtOH to give
75% I.HCl. Stereoisomers of I and analogs R₂C:CH(CH₂)_nR₁R₂ [NR₁R₂ =
NHCMe₃, (substituted)piperazinyl, NMe₂, piperidino, morpholino, etc; n =
1,2,3] were prepd. by the reaction of II with the appropriate amine.
Several of these compds. increased blood flow in the arteriae vertebrales
and femoralis in dogs.
IT 67822-07-5P 67822-08-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cerebral vasodilatory activity of)
RN 67822-07-5 CAPLUS
CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-phenyl-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

RN 67822-08-6 CAPLUS
CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(2-methylphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



IT 79438-34-9P 79438-35-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and dehydration of)


RN 79438-34-9 CAPLUS

CN 1-Piperazinepropanol, 4-(2-methoxyphenyl)-.alpha.,.alpha.-di-3-thienyl-,
(2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 67821-80-1

CMF C22 H26 N2 O2 S2



CM 2


intermed ?

1026

excluded

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 79438-35-0 CAPLUS
CN 1-Piperazinepropanol, 4-(3-methoxyphenyl)-.alpha.,.alpha.-di-3-thienyl-,
(2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 67821-86-7
CMF C22 H26 N2 O2 S2



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




IT 67822-00-8P 67822-01-9P 67822-02-0P


67822-03-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 67822-00-8 CAPLUS


CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(2-methoxyphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

RN 67822-01-9 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(4-fluorophenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)


RN 67822-02-0 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(4-methoxyphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



RN 67822-03-1 CAPLUS

CN Piperazine, 1-(3,4-dimethylphenyl)-4-(3,3-di-3-thienyl-2-propenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



=> d bib abs hitstr 17

L13 ANSWER 17 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1978:579845 CAPLUS

DN 89:179845

TI Dithienylalkylamines

IN Kleemann, Axel; Nubert, Ingomar; Stroman, Fritz; Thiemer, Klaus

PA Deutsche Gold- und Silber-Scheideanstalt vorm. Roessler, Ger.

SO Ger. Offen., 64 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2800535	A1	19780713	DE 78-2800535	19780107
	GB 1597591	A	19810909	GB 77-1121	19770112
	GB 1597593	A	19810909	GB 80-22580	19770112
	GB 1597592	A	19810909	GB 80-42000	19770112
	US 4206213	A	19800603	US 78-867157	19780105
	BE 862800	A1	19780710	BE 78-46306	19780110
	DD 136265	C	19790627	DD 78-203159	19780110
	DD 142883	C	19800716	DD 78-212127	19780110
	FI 7800083	A	19780713	FI 78-83	19780111
	DK 7800124	A	19780713	DK 78-124	19780111
	NO 7800101	A	19780713	NO 78-101	19780111
	SE 7800326	A	19780713	SE 78-326	19780111
	NL 7800350	A	19780714	NL 78-350	19780111
	ES 465896	A1	19780916	ES 78-465896	19780111
	ES 465897	A1	19780916	ES 78-465897	19780111
	ZA 7800174	A	19781129	ZA 78-174	19780111
	IN 147465	A	19800308	IN 78-CA35	19780111
	SU 747426	D	19800723	SU 78-2563907	19780111
	AT 7800189	A	19801015	AT 78-189	19780111
	AT 362355	B	19810511		
	HU 20344	O	19810728	HU 78-DE1033	19780111
	HU 177978	P	19820228		
	HU 20590	O	19810828	HU 78-DE949	19780111
	HU 178208	P	19820328		
	FR 2377396	A1	19780811	FR 78-792	19780112
	FR 2377396	B1	19820507		
	JP 53101362	A2	19780904	JP 78-2333	19780112
	AU 7832392	A1	19790719	AU 78-32392	19780112
	AU 522750	B2	19820624		
	FR 2382449	A1	19780929	FR 78-19759	19780703
	FR 2382449	B1	19820219		
	US 4254269	A	19810303	US 79-56838	19790712
	US 4281010	A	19810728	US 79-56840	19790712
	AT 7907073	A	19801015	AT 79-7073	19791102
	AT 362356	B	19810511		
	IN 149408	A	19811128	IN 80-CA92	19800125
	NO 8203010	A	19780713	NO 82-3010	19820906
PRAI	GB 77-1121		19770112		
	GB 77-1120		19770112		
	US 78-867157		19780105		
	AT 78-189		19780111		
	IN 78-CA35		19780111		

103

GI



AB Vasodilator (no data) dithienylalkylamines I [X = C(OH)CH₂, C:CH; X₁ = C1-5 alkylene; R = C3-7 cycloalkyl, optionally substituted CH₂Ph, C1-6 alkyl, aminoalkyl, phenylpiperazino] were prep'd. Thus, treating 3-bromothiophene with BuLi and BrCH₂CH₂CO₂Et gave 96%

1,1-bis(3-thienyl)-3-

bromo-1-propanol, which (45.5 g) was treated with 25 g p-hydroxynorephedrine to give 15 g II [X = C(OH)CH₂]. The last was dehydrated to II (X = C:CH) with HCl.

IT 67821-81-2P 67821-87-8P 67822-00-8P

67822-01-9P 67822-02-0P 67822-03-1P

67822-06-4P 67822-07-5P 67822-08-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)


RN 67821-81-2 CAPLUS

CN 1-Piperazinepropanol, 4-(2-methoxyphenyl)-.alpha.,.alpha.-di-3-thienyl-, (2Z)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 67821-80-1

CMF C22 H26 N2 O2 S2




CM 2

CRN 110-16-7

Applied
102

CMF C4 H4 O4
CDES 2:Z


Double bond geometry as shown.



RN 67821-87-8 CAPLUS
CN 1-Piperazinepropanol, 4-(3-methoxyphenyl)-.alpha.,.alpha.-di-3-thienyl-,
(2Z)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 67821-86-7
CMF C22 H26 N2 O2 S2



CM 2


CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 67822-00-8 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(2-methoxyphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 67822-01-9 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(4-fluorophenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 67822-02-0 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(4-methoxyphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 67822-03-1 CAPLUS

CN Piperazine, 1-(3,4-dimethylphenyl)-4-(3,3-di-3-thienyl-2-propenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 67822-06-4 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(2-ethoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 67822-07-5 CAPLUS

CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-phenyl-, dihydrochloride
(9CI) (CA INDEX NAME)

• 2 HCl

RN 67822-08-6 CAPLUS


CN Piperazine, 1-(3,3-di-3-thienyl-2-propenyl)-4-(2-methylphenyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



=> d bib abs hitstr 18

L13 ANSWER 18 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1977:170993 CAPLUS
DN 86:170993
TI Agents acting on the central nervous system: Part XXVI. Synthesis of
some diphenylpropylamine and dibenzocycloheptenylolethylamine derivatives
AU Plilai, K. M. R.; Prasad, C. R.; Kapil, R. S.
CS Cent. Drug Res. Inst., Lucknow, India
SO Indian J. Chem., Sect. B (1976), 14B(9), 714-16
CODEN: IJSBDB
DT Journal
LA English
GI

Applied




AB Ph₂CHCH₂CH₂NRR₁ or the dibenzocycloheptenes I [R₁ = H, R₂ = CH₂CH₂NMe₂, cyclopentyl, indol-2-ylethyl, (2-aminoethyl)cyclopentyl, or NR₁R₂ = 1,2,3,4-tetrahydro-1-quinolyl, 4-phenyl-1-piperazinyl] were prepd. by condensation of Ph₂C:CHCHO, Ph₂C:CHCH₂Br, or the dibenzocycloheptenes II or III with the appropriate amines. None of the compds. had significant activities on the cardiovascular or central nervous system.

IT 62469-23-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and pharmacol. activities of)

RN 62469-23-2 CAPLUS

CN Piperazine, 1-(3,3-diphenylpropyl)-4-phenyl, dihydrochloride (9CI) (CA INDEX NAME)



1026



BERNHARDT


09/127059

Page 41

=> d bib abs hitstr 19

L13 ANSWER 19 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1976:463094 CAPLUS
 DN 85:63094
 TI s-Triazines
 PA Science Union et Cie.-Societe Francaise de Recherche Medicale, Fr.
 SO Japan. Kokai, 5 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49076887	A2	19740724	JP 72-119721	19721129
GI					




AB The triazines I (R = CH₂Ph, halogen, OMe, substituted benzyl or benzhydryl; R₁ = CH₂CH:CR₂R₃, R₂, R₃ = H, halogen, Me; R₁ = CH₂C.tplbond.CR₄, R₄ = H, Me) were prep. by condensing the bis(chloroethyl)triazines II with H₂NR. Thus, 33 g II (R₁ = CH₂CH:CH₂) was heated 10 hr at 150.degree. with 46 g piperonylamine in diglyme and the product was treated with HCl to give 18 g I (R = piperonyl, R₁ = CH₂CH:CH₂).HCl. Among 17 addnl. I.bul.HCl prepd. were (R = piperonyl throughout): R₁ = CH₂CH:CMe₂, CH₂CH:CHMe, CH₂C.tplbond.CH, CH₂CH:CHCl.

IT 27469-55-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 27469-55-2 CAPLUS


CN 1,3,5-Triazine-2,4-diamine,
 6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-N,N'-
 di-2-propenyl- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 20

L13 ANSWER 20 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1976:421479 CAPLUS
DN 85:21479
TI s-Triazine derivatives
IN Regnier, Gilbert; Canevari, Roger
PA Science Union et Cie.-Societe Francaise de Recherche Medicale, Fr.
SO Can., 13 pp.
CODEN: CAXXA4
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 983497	A1	19760210	CA 72-157707	19721128
GI	For diagram(s), see printed CA Issue.				
AB	Eighteen piperazinyltriazines I (R = H2C:CHCH2, Me2C:CHCH2, HC.tplbond.CCH2, ClCH:CHCH2, MeCH:CHCH2; R1 = 3,4-methylenedioxybenzyl, 3,4-(MeO)2C6H3CH2, 2,3,4-(MeO)3C6H2CH2, Ph2CH, (p-ClC6H4)2CH, etc.) were prepd. by treating II with R1NH2.				
IT	27469-55-2P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	27469-55-2 CAPLUS				
CN	1,3,5-Triazine-2,4-diamine, 6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-N,N'- di-2-propenyl- (9CI) (CA INDEX NAME)				



X

=> d bib abs hitstr 21

L13 ANSWER 21 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1974:425292 CAPLUS

DN 81:25292

TI Diphenylaminoalkanamines, alkanamides, and .mu.-amino-N,N-diphenylalkanamides as potential biodynamic agents

AU Ananthanarayanan, C. V.; Rastogi, Shri N.; Srimal, R. C.; Anand, Nitya

CS Cent. Drug Res. Inst., Lucknow, India

SO Indian J. Chem. (1974), 12(1), 31-7

CODEN: IJOCAP

DT Journal

LA English

AB Ph2N(CH2)nR [R = Et2N, Me2CHNH, morpholino, piperidino, etc. throughout;
n

= 3 (I), 2 (II)], Ph2NCH2CH2COR (III), and Ph2NCO(CH2)nR (IV, n = 1-3) were prepd. starting from N-(.omega.-bromoalkyl)diphenylamines, Ph2NCH2CH2CO2H and .omega.-chloro-N,N-diphenylalkanamides, resp. I could also be prepd. by LAH (LiAlH4) redn. of III, but LAH redn. of IV led to dismutation of the mol. forming Ph2NH and .omega.-aminoalkanols. The compds. synthesized are in general CNS depressants; some of them also


show weak anorexic, hypotensive and antiinflammatory activities. A few of them show significant in vitro amoebicidal activity. (Biol. activity data given).

IT 52850-18-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 52850-18-7 CAPLUS

CN 1-Piperazineethanamine, N,N,4-triphenyl- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 22

L13 ANSWER 22 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1973:136216 CAPLUS
DN 78:136216
TI Synthesis of cyclic phosphoramidate piperazine derivatives with probable
antitumor activity
AU Zikolova, Sv.; Elenska, M.; Sheikova, G.
CS Bulg.
SO Tr. Nauchnoizsled. Khim.-Farm. Inst. (1972), 8, 69-76
CODEN: TKZGAG
DT Journal
LA Bulgarian
AB Piperazines (I; R = R1, Me, PhCH2, Ph2CH, Ph2CHCH2, .alpha.-C10H7CH2,
YCH2CH2; Y = Ph, Ph2CH, PhO, PhOCH2, Me2N, Et2N, pyrrolidino, piperidino,
morpholino) were treated with 2-chlorotetrahydro-2-oxo-2H-1,3,2-
oxazaphosphorin (II) in C2H4Cl2 contg. Et3N at -5 to 0.degree. to give
the
corresponding oxazaphosphorinylpiperazines (III) in 30-76% yield. III
thus prepd. have antitumor activity against Staphylococcus aureus UF-2
and
UF-3 comparable to that of Myleran at 1250-2500 .gamma./ml; the antitumor
activity of III (R = PhCH2, .alpha.-C10H7CH2) exceeded that of Myleran at
25-125 .gamma./ml.
IT 41379-11-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 41379-11-7 CAPLUS
CN 2H-1,3,2-Oxazaphosphorine, 2-[4-(3,3-diphenylpropyl)-1-
piperazinyl]tetrahydro-, 2-oxide, ethanedioate (1:1) (9CI) (CA INDEX
NAME)
CM 1
CRN 48218-74-2
CMF C22 H30 N3 O2 P



X


CM 2
CRN 144-62-7

BERNHARDT

09/127059



Page 46

CMF C2 H2 O4





=> d bib abs hitstr 23

L13 ANSWER 23 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1972:539981 CAPLUS
 DN 77:139981
 TI Central nervous system depressants. New purine derivatives
 AU Regnier, G.; Canevari, R.; Le Douarec, J. C.; Laubie, M.
 CS Lab. Servier, Sci. Union et Cie, Suresnes, Fr.
 SO Chim. Ther. (1972), 7(3), 192-205
 CODEN: CHTPBA
 DT Journal
 LA French
 GI For diagram(s), see printed CA Issue.
 AB Piperazinopurines (I, R = aryl, aralkyl, 2-pyridinyl, 2-pyrimidinyl; R1 = H, Me, allyl, CH₂CH₂OH, CH₂CH(OH)CH₂OH, piperonyl, o-MeOC₆H₄) and their 6-piperazinopurine analogs (52 compds.) were prepd. by cyclizing the diaminopyrimidine with HC(OEt)₃-Ac₂O or HOAc-HCONH₂. The 6,9-disubstituted purines were obtained by treating the 6-chloropurine with the piperazine deriv. I (R1 = CH₂CH(OH)CH₂OH) were obtained by treating I (R = H) with ClCH₂CH(OH)CH₂OH and NaH. Besides their central nervous system depressant activity the piperazinopurines showed some adrenolytic and antiinflammatory activity.
 IT 24926-63-4P 37425-11-9P 37425-12-0P
 37425-13-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 24926-63-4 CAPLUS
 CN 1H-Purine, 6-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 37425-11-9 CAPLUS
 CN 1H-Purine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 37425-12-0 CAPLUS
CN 1H-Purine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47770-05-8
CMF C30 H30 N6



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 37425-13-1 CAPLUS
CN 9H-Purine, 9-(2-propenyl)-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47806-67-7
CMF C33 H34 N6



CM 2

CRN 75-75-2
CMF C H4 O3 S



=> d bib abs hitstr 24

L13 ANSWER 24 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1972:148745 CAPLUS

DN 76:148745

TI Triphenylpropylpiperazine derivatives as new potent analgetic substances

AU Regnier, G. L.; Canevari, R. J.; Le Douarec, J. C.; Holstorp, S.; Daussy, J.

CS Chem. Res. Div., Sci. Union et Cie., Suresnes, Fr.

SO J. Med. Chem. (1972), 15 295-301

CODEN: JMCMAR

DT Journal

LA English

AB Sixty-four 1-triphenylpropyl 4-heterocyclic substituted piperazines (I) with a methadone-like structure were prepd., e.g., by condensation of haloheterocycles or 2-methylthiopyrimidine with N-monosubstituted piperazines or the Cl atom of a 1-substituted 4-(chloropyridazinyl or s-triazinyl)piperazine was hydrogenolyzed under pressure over Pd/C. Structure I was divided into 4 portions and each one varied selectively. To explain complicated structure-analgesic activity relations 1-(3,3,3-triphenylpropyl)-4-(2-pyrimidyl)piperazine (II) [20980-06-7], having analgetic potency between that of morphine and codeine, was used to illustrate how modifications in its 4 main parts

(see

I) influence analgesic activity (mice hot plate test and phenylquinone writhing test). The presence of only 2 Ph groups in part A of II abolished analgesic properties. In part B, the introduction of an addnl. CH2 decreased activity. In part C, any modification of the piperzine

ring

was unfavorable. In part D the kind of heterocyclic nucleus closely

detd.

activity, the order of activity being pyrazinyl > pyrimidyl > pyridyl > pyridazinyl > triazinyl. 1-(3,3,3-Triphenylpropyl)-4-(2-pyrazinyl)piperazine (III) [34675-79-1] was the most active in the series but induced bizarre behavioral effects after cessation of a 3-week treatment. 1-(3,3,3-Triphenylpropyl)-4-(4-allylamino-2-pyrimidyl)piperazine (IV) [20980-18-1] antagonized the actions of II and III while increasing the morphine effect. 1-(3,3,3-Triphenylpropyl)-4-(3-pyridazinyl)piperazine (V) [34675-81-5] was pharmacol. similar to codeine [76-57-3].

IT 20980-06-7 20980-11-4 20980-12-5

20980-13-6 20980-14-7 20980-16-9

20980-17-0 20980-18-1 21026-25-5

21162-92-5 21801-31-0 34675-79-1

34675-81-5 36371-39-8 36371-40-1

36371-41-2 36371-43-4 36371-45-6

36371-60-5 36371-61-6 36524-61-5

36524-62-6 36524-71-7 36524-72-8


36524-74-0 36524-75-1 36524-78-4

36524-80-8 36524-82-0 36524-83-1


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (analgesic activity of)

RN 20980-06-7 CAPLUS


CN Pyrimidine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-11-4 CAPLUS
CN Pyrimidine, 4-methyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)



RN 20980-12-5 CAPLUS
CN Pyrimidine, 4,6-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-13-6 CAPLUS
CN Pyrimidine, 4-methoxy-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-14-7 CAPLUS

CN 4-Pyrimidinamine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 20980-16-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 20980-17-0 CAPLUS

CN 4-Pyrimidinamine,
N,N-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)

Me₂N

RN 20980-18-1 CAPLUS

CN 4-Pyrimidinamine,

N-2-propenyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)


RN 21026-25-5 CAPLUS

CN Pyrimidine, 4,5-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47758-61-2

CMF C31 H34 N4



CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.


HO₂C E CO₂H

RN 21162-92-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 21801-31-0 CAPLUS
CN Piperazine, 1-(2-pyridinyl)-4-(3,3,3-triphenylpropyl)- (9CI) (CA INDEX NAME)




RN 34675-79-1 CAPLUS
CN Pyrazine, [4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 34675-81-5 CAPLUS

CN Pyridazine, 3-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36371-39-8 CAPLUS


CN Pyridazine, 3-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36371-40-1 CAPLUS

CN Pyrazine, [4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

excl v dem



• 2 HCl

RN 36371-41-2 CAPLUS


CN Pyrimidine,

2-[4-[3-(4-methoxyphenyl)-3,3-diphenylpropyl]-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 47758-59-8


CMF C30 H32 N4 O



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 36371-43-4 CAPLUS
CN Pyrimidine, 2-[4-(2-methyl-3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47738-67-0
CMF C30 H32 N4



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 36371-45-6 CAPLUS
CN Pyrazine, [4-(2-methyl-3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 47738-66-9
CMF C30 H32 N4



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 36371-60-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-ethoxy-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 36371-61-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-ethoxy-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-61-5 CAPLUS


CN 4-Pyrimidinamine, N-cyclopropyl-N-methyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



• 2 HCl


RN 36524-62-6 CAPLUS

CN 4-Pyrimidinamine, N-2-cyclopenten-1-yl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-71-7 CAPLUS


CN 3-Pyridazinamine, 6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



CH₂-CH₂-CPh₃


RN 36524-72-8 CAPLUS

CN 3-Pyridazinamine,
N-2-propenyl-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
dihydrochloride (9CI) (CA INDEX NAME)



• 2 HCl

RN 36524-74-0 CAPLUS
CN Pyrazine, 2,5-dimethyl-3-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




• 2 HCl

RN 36524-75-1 CAPLUS
CN Pyrazinamine, 3-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 47739-03-7
CMF C29 H31 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 36524-78-4 CAPLUS

CN Pyrazine, 2-methyl-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI)

(CA

INDEX NAME)


Me




RN 36524-80-8 CAPLUS

CN 1,3,5-Triazin-2-amine, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI)

(CA INDEX NAME)




RN 36524-82-0 CAPLUS
 CN 1,3,5-Triazine-2,4-diamine, N,N'-di-2-propenyl-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-83-1 CAPLUS
 CN Piperazine, 1-(2-thiazolyl)-4-(3,3,3-triphenylpropyl)-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47693-41-4
 CMF C28 H29 N3 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S




IT 20980-09-0P 20980-15-8P 20980-19-2P
 20980-20-5P 21026-26-6P 21026-27-7P
 36371-38-7P 36371-42-3P 36371-47-8P
 36371-48-9P 36371-50-3P 36371-51-4P
 36371-52-5P 36371-57-0P 36371-62-7P
 36371-63-8P 36371-64-9P 36371-65-0P
 36478-02-1P 36524-54-6P 36524-55-7P
 36524-60-4P 36524-63-7P 36524-64-8P
 36524-65-9P 36524-70-6P 36524-73-9P
 36524-76-2P 36524-77-3P 36524-79-5P
 36524-81-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)


RN 20980-09-0 CAPLUS

CN Pyrimidine, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA
 INDEX NAME)




RN 20980-15-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA
 INDEX NAME)




RN 20980-19-2 CAPLUS
 CN Quinazoline, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
 dihydrochloride
 (8CI, 9CI) (CA INDEX NAME)



● 2 HCl


RN 20980-20-5 CAPLUS
 CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA
 INDEX NAME)



RN 21026-26-6 CAPLUS
 CN Quinazoline, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47787-36-0
 CMF C33 H32 N4




CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.

E CO₂H
HO₂CRN 21026-27-7 CAPLUS
CN Quinazoline, 2-methyl-4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 47796-32-7
CMF C34 H34 N4

CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.

E CO₂H
HO₂CRN 36371-38-7 CAPLUS
CN 1-Piperazinebutanenitrile, .alpha.,.alpha.-diphenyl-4-(2-pyrimidinyl)-
(9CI) (CA INDEX NAME)




excluded

RN 36371-42-3 CAPLUS
 CN Pyrimidine, 2-[4-(3-[1,1'-biphenyl]-4-yl-3,3-diphenylpropyl)-1-piperazinyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47806-65-5
 CMF C35 H34 N4




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 36371-47-8 CAPLUS
CN Pyrimidine, 2-[3-methyl-4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 36371-48-9 CAPLUS
CN Pyrimidine, 2-[2-methyl-4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 36371-50-3 CAPLUS
CN Quinoxaline, decahydro-1-(2-pyrimidinyl)-4-(3,3,3-triphenylpropyl)- (9CI)
(CA INDEX NAME)


CN Pyrimidine, 4,5,6-trimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)




RN 36371-62-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid,
2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
ethyl ester (9CI) (CA INDEX NAME)




RN 36371-63-8 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)




RN 36371-64-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N,N-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36371-65-0 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)

RN 36478-02-1 CAPLUS

CN ~~Pyrimidine, 4,6-dimethyl-5-phenyl-2-[4-(3,3,3-triphenylpropyl)-1-~~
~~piperazinyl]- (9CI) (CA INDEX NAME)~~


RN 36524-54-6 CAPLUS

CN Pyrimidine, 5-chloro-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI)
(CA INDEX NAME)




RN 36524-55-7 CAPLUS

CN 5-Pyrimidinesulfonamide, N,N-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-60-4 CAPLUS


CN ~~4-Pyrimidinamine, N-(2-phenylethyl)-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)~~



• 2 HCl


RN 36524-63-7 CAPLUS

CN 4,5-Pyrimidinediamine, N4-2-propenyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-64-8 CAPLUS

CN 4-Pyrimidinamine, N-(3-methyl-2-butenyl)-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 36524-65-9 CAPLUS

CN 5-Pyrimidinemethanamine, N,N-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 47787-37-1

CMF C32 H37 N5




CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 36524-70-6 CAPLUS

CN Pyridazine, 3-methyl-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI)
 (CA INDEX NAME)

RN 36524-73-9 CAPLUS


CN 3-Pyridazinamine, N-(3-methyl-2-butenyl)-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 36524-76-2 CAPLUS
CN Pyrazinamine, 6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dimethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 47739-04-8
CMF C29 H31 N5




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 36524-77-3 CAPLUS
CN Pyrazinamine, N-2-propenyl-6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36524-79-5 CAPLUS
 CN 1,3,5-Triazine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 36524-81-9 CAPLUS
 CN 1,3,5-Triazine-2,4-diamine, 6-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
 dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 47758-60-1
 CMF C28 H31 N7



CM 2

CRN 75-75-2


CMF C H4 O3 S



=>


=> d bib abs hitstr 25

L13 ANSWER 25 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1971:431808 CAPLUS
DN 75:31808
TI Antimicrobial activity of piperazine derivatives and related compounds
AU Patel, Madhuben R.; Bellare, Ramesh A.; Deliwala, Chimanlal V.
CS Dep. Chemother., Haffkine Inst., Bombay, India
SO Indian J. Exp. Biol. (1971), 9(1), 117-19
CODEN: IJEBA6
DT Journal
LA English
GI For diagram(s), see printed CA Issue.
AB Basic benzhydryl ethers, thioethers, and ethylenediamine derivs. contg. a piperazine ring (I, R = -NHCH₂CH₂-, -SCH₂CH₂-, -OCH₂CH₂-, -O(CH₂)₄-, -CH₂CO-, or -CH₂CH₂- and R₁ = alkyl, aralkyl, or other aromatic groups) were tested for in vitro activity against gram pos. and gram neg. bacteria, Vibrio comma, Mycobacterium tuberculosis, yeast, and fungi. None of the compds. showed significant activity against Candida albicans, and a very low order of activity was obsd. against Salmonella typhi, Vibrio comma, and Staphylococcus aureus. A majority of the compds. showed activity against M. tuberculosis (64 out of 79 compds. tested) but significant activity was confined to the ethylenediamine series (I, R = -NHCH₂CH₂-). The most active antituberculosis compds. were N'-[(p-chloro-phenylbenzylamino)ethyl]-N-(2-hydroxypropyl)piperazine, N'-[(p-chlorophenylbenzylamino)ethyl]-N-(m-methylbenzyl)piperazine, N'-[(p-chlorophenylbenzylamino)ethyl]-N-(o-methoxyphenyl)piperazine, and N'-[(p-chlorophenylbenzylamino)ethyl]-N-(2-thiazolyl)piperazine, with min. inhibitory concn. of 5 .mu.g/ml.
IT 33656-13-2 33656-14-3 33656-15-4
33656-16-5 33656-17-6 33656-18-7
33656-19-8 33656-21-2
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(bactericidal activity of)
RN 33656-13-2 CAPLUS
CN Piperazine, 1-(o-chlorophenyl)-4-[3-(p-chlorophenyl)-3-phenylpropyl]-(8CI) (CA INDEX NAME)




excluded.

RN 33656-14-3 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(o-methoxyphenyl)-
(8CI) (CA INDEX NAME)




RN 33656-15-4 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-o-tolyl- (8CI) (CA
INDEX NAME)




excluded

RN 33656-16-5 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-m-tolyl- (8CI) (CA
INDEX NAME)



RN 33656-17-6 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-p-tolyl- (8CI) (CA
INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 33656-18-7 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(2-pyridyl)- (8CI)
(CA INDEX NAME)



RN 33656-19-8 CAPLUS

CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(2-thiazolyl)- (8CI)
(CA INDEX NAME)




RN 33656-21-2 CAPLUS

CN Pyrimidine, 2-[4-[3-(p-chlorophenyl)-3-phenylpropyl]-1-piperazinyl]-
(8CI)
(CA INDEX NAME)

BERNHARDT

09/127059

Page 6



=> d bib abs hitstr 26

L13 ANSWER 26 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1970:520681 CAPLUS

DN 73:120681

TI s-Triazine derivatives, and their analeptic respiratory activity

PA Science Union et Cie.-Societe Francaise de Recherche Medicale

SO Belg., 14 pp.

CODEN: BEXXAL

DT Patent

LA Unavailable

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 739283	A	19700323	BE 69-739283	19690923
	GB 1256513	A	19711208	GB 68-46802	19681002
	AT 291271	B	19710712	AT 69-8674	19690912
	ES 371943	A1	19711116	ES 69-371943	19690926
	CH 517754	A	19720115	CH 69-517754	19690926
	US 3647794	A	19720307	US 69-861448	19690926
	SE 350498	B	19721030	SE 69-13373	19690929
	NL 6914749	A	19700406	NL 69-14749	19690930
	NO 124996	B	19720703	NO 69-3917	19691001
	BR 6912898	A0	19730524	BR 69-212898	19691001
	DK 129656	B	19741104	DK 69-5228	19691001
	FI 49512	B	19750401	FI 69-2827	19691001

PRAI GB 68-46802 19681002

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), with low toxicity and with analeptic effect on respiration, were prepd. Thus, DMF contg.

4,6-bis(allylamino)-2-chloro-s-triazine and 1-piperonylpiperazine was refluxed 9 hr and treated with iso-PrOH satd. with dry HCl to give 52.3% I(R = allyl, R1 = piperonyl).-2HCl. Similarly were prepd. 23 related compds. either as

free bases or salts.

IT 27469-55-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 27469-55-2 CAPLUS

CN 1,3,5-Triazine-2,4-diamine,

6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-N,N'-
di-2-propenyl- (9CI) (CA INDEX NAME)

H₂C=CH-CH₂-NH



X

=> d bib abs hitstr 27

L13 ANSWER 27 OF 32 CAPLUS COPYRIGHT 1999 ACS
 AN 1970:121586 CAPLUS
 DN 72:121586
 TI 2-Piperazino-4,6-bis(allylamino)-sym-triazines against respiration
 insufficiency
 IN Regnier, Gilbert; Canevari, Roger; Laubie, Michel
 PA Science Union et Cie.-Societe Francaise de Recherche Medicale
 SO Ger. Offen., 16 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1947332	A	19700409	DE 69-1947332	19690918
	DE 1947332	C3	19730412		
	GB 1256513	A	19711208	GB 68-46802	19681002
	AT 291271	B	19710712	AT 69-8674	19690912
	ES 371943	A1	19711116	ES 69-371943	19690926
	CH 517754	A	19720115	CH 69-517754	19690926
	US 3647794	A	19720307	US 69-861448	19690926
	SE 350498	B	19721030	SE 69-13373	19690929
	NL 6914749	A	19700406	NL 69-14749	19690930
	NO 124996	B	19720703	NO 69-3917	19691001
	BR 6912898	A0	19730524	BR 69-212898	19691001
	DK 129656	B	19741104	DK 69-5228	19691001
	FI 49512	B	19750401	FI 69-2827	19691001

PRAI GB 68-46802 19681002

GI For diagram(s), see printed CA Issue.

AB s-Triazines (I), respiratory analeptics, were prepd. from the
 corresponding 2-chloro derivs. and piperazines. Thus, 0.0443 mole
 4,6-bis(allylamino)-2-chloro-s-triazine and 0.0886 mole
 1-piperonylpiperazine in 300 ml HCONMe₂ was refluxed 9 hr at 150.degree.
 and acidified to give 52.3% I.2HCl (R = piperonyl, R₁ = CH:CH₂), m.
 228-9.degree.. Similarly prepd. were I (R₁ = CH:CH₂) (R, salt, and m.p.
~~salt given): 3,4-(ethylenedioxy)-benzyl, fumarate monohydrate,~~
 105-15.degree. (decompn.); 3,4-(MeO)2C6H3CH₂, fumarate, 105-12.degree.;
 2,3,4-(MeO)3C6H2CH₂, di hydrochloride monohydrate, 167-73.degree.;
 4-FC6H4CH₂, dihydrochloride, 220-5.degree.; Ph, dihydrochloride,
 220-4.degree.; 2-MeOC6H4, dihydrochloride, 202-21.degree. (decompn.);
 3-F3CC6H4, base, 115.degree.; 2-pyridyl, dihydrochloride monohydrate,
 212-14.degree.; 2-pyrimidinyl, dihydrochloride hemihydrate,
 228-32.degree.; 2-pyrazinyl, dihydrochloride dihydrate, 318-25.degree.;
 PhCH2CH2, dihydrochloride, 239-47.degree.; PhCH2CHMe, base,
 100-3.degree.;
 PhCH:CHCH2, dihydrochloride 2.5-hydrate, 215-22.degree.; Ph2CH,
 bis(methanesulfonate), 220-31.degree.; (4-FC6H4)2CH, base,
 175-80.degree.;
 (4-ClC6H4)2-CH, bis(methanesulfonate), 236-40.degree.; Ph2CHCH2CH2, base,
 104-8.degree.; H, dihydrochloride, 259-63.degree.. I.2HCl (R =
 piperonyl,
 R₁ = CH:CMe₂), m. 222-7.degree., I (R = piperonyl, R₁ = CH:-CHMe)
 fumarate, m. 155-8.degree., I (R = (4-FC6H4)2CH, R₁ = trans-CH:CHCl], m.
 124.degree., and I.2HCl (R = piperonyl, R₁ = C.tplbond.CH), m.
 180-220.degree. (decompn.) were also prepd. I and their salts have low


toxicity; LD50 (mice) 50-400 or 400- >2000 mg/kg when applied i.p. or per os. resp.

IT 27469-55-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 27469-55-2 CAPLUS

CN 1,3,5-Triazine-2,4-diamine,
6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-N,N'-
di-2-propenyl- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 28

L13 ANSWER 28 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1970:55401 CAPLUS'

DN 72:55401

TI Syntheses of N-heterocyclic compounds. I. Syntheses of 2,4,5-trisubstituted pyrimidine derivatives

AU Yurugi, Shojiro; Tomimoto, Mitsumi; Fushimi, Tomiyoshi

CS Takeda Chem. Ind. Ltd., Osaka, Japan

SO Takeda Kenkyusho Nempo (1969), 28, 1-11

CODEN: TDKNAF

DT Journal

LA Japanese

GI For diagram(s), see printed CA Issue.

AB I were prepd. by the condensation reaction of $R_1C(:NH)NH_2$ with $EtOCH:C(CO_2Et)_2$ or by the replacement reaction of

2-(methylthio)-4-hydroxy-

5-(ethoxycarbonyl)pyrimidine with amines. I were treated with amines to give II. III, obtained from 2-(methylthio)-4-chloro-5-(ethoxycarbonyl)pyrimidine (IV), were treated with 1-benzylpiperidine to give V. Reaction of IV with $HN(CH_2CH_2OH)_2$ gave 96.8% VI, m. 145.degree.. The following I were prepd. (R_1 , % yield, and m.p. given): morpholino, 55.3, 163-4.degree.; pyrrolidinyl, 43.5, 192-3.degree.; piperidyl, 23.9, 142-3.degree.; 1-benzylpiperazinyl, 35.8, 147-8.degree.; 1-(2-hydroxyethyl)piperazinyl, 63.3, 130.degree. (decompn.); 1-(2,3,4-trimethoxybenzyl)piperazinyl, 87.8, 105-7.degree.; 1-(3,4-dimethoxybenzyl)piperazinyl, 68.2, 147-50.degree.; 1-(diphenylmethyl)piperazinyl, 89, 236.degree.; 1-(3,3-diphenylpropyl)piperazinyl, 80.0, 133-5.degree.; 1-(2-phenethyl)piperazinyl, 90.0, 185-6.degree.; 1-(3,4-methylenedioxybenzyl)piperazinyl, 89.0, 153-4.degree.; 2-piperidylethylamino,

47.7,

146.degree. (di-HCl salt, m. 220-3.degree.); and

2-hydroxyphenethyl-amino,

26.4, 242-3.degree.. The II prepd. were as follows (R_2 , R_3 , % yield, and m.p. given): $C_5H_{11}NH$, $NHNH_2$, 53.0, 218-20.degree.; iso- $C_5H_{11}NH$, $NHNH_2$, 53.0, 214-15.degree.; $PhCH_2NH$, $NHNH_2$, 55.0, 229-30.degree. (decompn.);

morpholino, morpholino, 30.6, 233-5.degree.; morpholino, $NHNH_2$, 70.0, 265.degree.; morpholino, $NHPr$ -iso, 76.0, 220-1.degree.; morpholino, 1-benzylpiperazinyl, 43.9, 120.degree. (decompn.); 1-benzylpiperazinyl, $NHNH_2$, 35.7, 213-15.degree.; $Ph-CH_2NH$, 1-benzylpiperazinyl, 67.8, 125-30.degree.; $PhCH_2NH$, $NH-Pr$ -iso, 58.0, 247-8.degree.; $PhCH_2NH$, morpholino, 62.5, 192-4.degree.; 1-(2-hydroxyethyl)piperazinyl, $NHPr$ -iso, 49.0, 204-5.degree.; 1-(2-hydroxyethyl)piperazinyl, 1-(2-hydroxyethyl)piperazinyl, 10.0, 75.degree. (decompn.); 1-(2-hydroxyethyl)piperazinyl, 1-benzylpiperazinyl, 53.3, 147-50.degree. (decompn.); 1-(2,3,4-trimethoxybenzyl)piperazinyl, morpholino, 54.8, 196-7.degree.; 1-benzylpiperazinyl, NH_2 , 51.0, 195-6.degree.; 1-(phenethyl)piperazinyl, morpholino, 86.8, 234.degree. (decompn.); 1-(3,4-dimethoxybenzyl)piperazinyl, morpholino, 100, 229.degree. (decompn.); 1-(3,3-diphenylpropyl)piperazinyl, morpholino, 71.4, 187.degree.; 1-(3,4-methylenedioxybenzyl)piperazinyl, morpholino, 87.6, 219.degree.; 1-(2,3,4-trimethoxybenzyl)-piperazinyl, $NHPr$ -iso, 43.5, 177.degree.; 2-hydroxyphenethylamino, morpholino, 44.6, 178-9.degree. (decompn.); 2-hydroxyphenethyl-amino, 1-benzylpiperazinyl, 28.0, 170-2.degree.; and $NHNH_2$, $NHNH_2$, 70, 275.degree.. The III prepd. were as follows (R_4 , % yield, and m.p. given): $NHPr$ -iso, 98.0, 50.degree.;


1-benzylpiperazinyl, 50.0, 178.degree. (decompn.); and NH(CH₂)₂NEt₂, 50.0, 178.degree. (decompn.). The V prepd. were as follows (R₅, % yield, and m.p. given): NH₂, 67.0, 130.degree.; NHCHMe₂, 72.0, 211.degree. (decompn.); NHCH₂-Ph, 60, 208.degree. (decompn.); 1-benzylpiperazinyl, 61.5, 230.degree. (decompn.); and NH(CH₂)₂NEt₂, 45.0, 220.degree. (decompn.). The NMR spectrum of VI is presented.

IT 25693-49-6P 25693-74-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 25693-49-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4-hydroxy-, ethyl ester (8CI) (CA INDEX NAME)



RN 25693-74-7 CAPLUS

CN Morpholine, 4-[[2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4-hydroxy-5-pyrimidinyl]carbonyl]- (8CI) (CA INDEX NAME)



=> d bib abs hitstr 29

L13 ANSWER 29 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1970:31840 CAPLUS
DN 72:31840
TI Analgesic and hypotensive 2-and 6-(4-substituted-1-piperazinyl) purines
IN Regnier, Gilbert; Canevari, Roger; Le Douarec, Jean C.; Laubie, Michel
PA Science Union et Cie. - Societe Francaise de Recherche Medicale
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3457263	A	19690722	US 67-694357	19671229
	GB 1165283	A	19690924	GB 67-2446	19670117
	BE 709014	A	19680705	BE 68-709014	19680105
	CH 490404	A	19700515	CH 68-490404	19680112
	FR 1550912	A	19681220	FR 68-1550912	19680115
	ES 349429	A1	19690401	ES 68-349429	19680117
	FR 7559	M	19691229	FR 68-7559	19680329
PRAI	GB 67-2446		19670117		

GI For diagram(s), see printed CA Issue.


AB To prep. title purines (I) chloro-substituted 4-amino-5-nitropyrimidines (II) were treated with N-monosubstituted piperazines (III) in a polar solvent, e.g. DMF (dimethylformamide) at 110-140.degree. 14 hr in the presence of an acid acceptor, e.g. Na2CO3. The resulting IV is hydrogenated at room temp. under 2-10 atm in the presence of a catalyst, e.g. Raney Ni. The resulting diamino compd. (V) is then cyclized to give I e.g. by heating it in an excess of ethyl orthoformate in the presence

of
Ac2O 6 hr at 110-30.degree.. Prepd. were 2-[4-(diphenylmethyl)-1-piperazinyl]-purine, m. 210-12.degree. (decompn.), bismethanesulfonate deriv. m. 229-311.degree.; 2-(4-cinnamylpiperazin-1-yl)purine, m. 260.degree.; 6-[4-(diphenylmethyl)-1-piperazinyl]purine, m. 275-6.degree.,

bismethanesulfonate deriv., m. 230.degree.. Other I prepd. were (R, R1, point of connection to the ring, and m.p. are given): piperonyl, H, 2, (di-HCl salt m. 195-6.degree.); o-methoxyphenyl, H, 2, 239-40.degree. (di-HCl salt 162-4.degree.); 3,3-diphenylpropyl, H, 2, 88-91.degree.; 2-pyrimidinyl, H, 2, 282-4.degree.; 2-pyrimidinyl, Me, 2, 195-8.degree.; diphenylmethyl, Me, 2, 193-5.degree.; piperonyl, H, 6, 257.degree.; cinnamyl, H, 6, 224.degree.; phenylisopropyl, H, 6, 215-17.degree.; o-methoxyphenoxyethyl, H, 6, 209.degree.; 2-phenylethyl, H, 6, 243.degree.; 3,3-diphenylpropyl, H, 6, 200.degree.; piperonyl, Me, 2, [bis(methanesulfonate) m. 236-40.degree.]; diphenylmethyl, HOCH2CH2, 2, 174.degree.; phenylisopropyl, H, 2, (di-HCl salt m. 261-7.degree.); 2-phenylethyl, H, 2, (di-HCl salt m. 258-63.degree.); o-methoxyphenoxyethyl, H, 2, [(bismethanesulfonate) m. 208-17.degree.]; piperonyl, HOCH2CH2, 2, (di-HCl m. 235-40.degree.; piperonyl, allyl, 2, (di-HCl salt m. 204-12.degree.); diphenylmethyl, allyl, 2, (di-HCl salt m. 257-59.degree.; diphenylmethyl, piperonyl, [2-(bismethane sulfonate) m. 140-44.degree.]; piperonyl, piperonyl, 2, (di-HCl salt 237-42.degree.); piperonyl, 2, -3-dihydroxypropyl, 2, 215-22.degree. (decompn.); 2-pyrimidinyl, H, 6, >350.degree.; o-methoxyphenyl, H, 6, [bis(methane sulfonate) m. 200-203.degree.]; piperonyl, HOCH2CH2, 6, -


(di-HCl salt m. 270.degree.); piperonyl, piperonyl, 6, (di-HCl salt m. 139-49.degree.); piperonyl, Me, 6, [bis(methanesulfonate) m. 197-200.degree.]; diphenylmethyl, piperonyl, 6, 154.degree.; diphenylmethyl, HOCH₂CH₂, 6, (di-HCl salt m. 213-17.degree.); cinnamyl, piperonyl, 6, 136.degree.; diphenylmethyl, 2,3-dihydroxypropyl, 6, 230-34.degree.; m-(trifluoromethyl)phenyl, H, 6, 280-87.degree.; 2-pyridinyl, H, 6, 300-305.degree.. IV prepd. were (R, R1, position of substitution, and m.p. given): piperonyl, H, 2, 157-8.degree.; o-methoxyphenyl, H, 2, 176.degree.; 3,3-diphenylpropyl, H, 2, 130.degree.; 2-pyrimidinyl, H, 2, 180-81.degree.; 2-pyrimidinyl, Me, 2, 231.degree.; diphenylmethyl, Me, 2, 197.degree.; diphenylmethyl, H, 2, 183.degree.; piperonyl, H, 4, 162.degree.; cinnamyl, H, 4, 155.degree.; phenylisopropyl, H, 4, 168.degree.; o-methoxyphenoxyethyl, H, 4, 110-12.degree.; phenylethyl, H, 4, 180.degree.; 3,3-diphenylpropyl, H, 4, 158.degree.; piperonyl, Me, 2, 150.degree.; diphenylmethyl, HOCH₂CH₂, 2, 163.degree.; cinnamyl, H, 2, 160.degree.; phenylisopropyl, H, 2, 190.degree.; phenylethyl, H, 2, 180.degree.; o-methoxyphenoxyethyl, H, 2, 120.degree.; piperonyl, HOCH₂CH₂, 2, 109.degree.; diphenylmethyl, allyl, 2, 134.degree.; diphenylmethyl, piperonyl, 2, 173.degree.; piperonyl, piperonyl, 2, 110.degree. (decompn.); piperonyl, 2,3-dihydroxypropyl, 2, (di-HCl salt m. 210-19.degree.). V prepd. were (R, R1, position of substitution, and m.p. given): diphenylmethyl, H, 2, 222.degree.; piperonyl, H, 2, 184.degree.; o-methoxyphenyl, H, 2, (tri-HCl salt m. 163-5.degree.); 3,3-diphenylpropyl, H, 2, [di-HCl salt m. 175-8.degree. (decompn.)]; 2-pyrimidinyl, H, 2, 175.degree.; 2-pyrimidinyl, Me, 2, 231.degree.; diphenylmethyl, Me, 2, 256.degree.; piperonyl, H, 4, 162.degree.; cinnamyl, H, 4, 149.degree.; phenylisopropyl, H, 4, 166.degree.; o-methoxyphenoxyethyl, H, 4, 180.degree.; phenylethyl, H, 4, 202.degree.; 3,3-diphenylpropyl, H, 4, 170.degree.; piperonyl, Me, 2, 140.degree.; diphenylmethyl, HOCH₂CH₂, 2, 176.degree.; cinnamyl, H, 2, (di-HCl salt m. 254-60.degree.); phenylisopropyl, H, 2, 112.degree.; phenylethyl, H, 2, 124-7.degree. [tri-HCl salt m. 190.degree. (decompn.)]; o-methoxyphenoxyethyl, H, 2, 106-110.degree. (tri-HCl salt m. 218-223.degree.); piperonyl, HOCH₂CH₂, 2, 94.degree. [tri-HCl salt m. 200.degree. (decompn.)]; piperonyl, allyl, 2, (an oil); diphenylmethyl, allyl, 2, 169.degree.; diphenylmethyl, piperonyl, 2, (an oil); piperonyl, piperonyl, 2, (an oil); piperonyl, 2,3-dihydroxypropyl, 2, [tri-HCl salt m. 200.degree. (decompn.)]. Other compds. prepd. were 6-chloro-9-(hydroxyethyl)purine m. 160.degree., 6-chloro-9-piperonyl-purine m. 164.degree., and 6-chloro-9-methylpurine m. 140.degree.; and these were used in the prepn. of I. Toxicol. and pharmacol. studies have shown that they have a low toxicity and therapeutic properties as antihypertensive, analgesic, and central nervous system depressants. The LD₅₀ studied by i.p. administration in mice varies from 88-600 mg/kg and from 360 to over 2000 mg/kg for peroral administration.

IT 24926-38-3P 24926-39-4P 24926-40-7P
24926-63-4P 24926-64-5P 24926-65-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 24926-38-3 CAPLUS
RN 24926-39-4 CAPLUS
CN Pyrimidine, 4,5-diamino-2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl


RN 24926-40-7 CAPLUS
 CN Pyrimidine, 4-amino-2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-5-nitro-
 (8CI) (CA INDEX NAME)



RN 24926-63-4 CAPLUS
 CN 1H-Purine, 6-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX
 NAME)



RN 24926-64-5 CAPLUS
 CN Pyrimidine, 4,5-diamino-6-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (8CI)
 (CA INDEX NAME)




RN 24926-65-6 CAPLUS
 CN Pyrimidine, 4-amino-6-[4-(3,3-diphenylpropyl)-1-piperazinyl]-5-nitro-
 (8CI) (CA INDEX NAME)

BERNHARDT

09/127059

Page 15



=> d bib abs hitstr 30

L13 ANSWER 30 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1969:501817 CAPLUS

DN 71:101817

TI Synthesis and central nervous system depressant activity of new piperazine

derivatives and related compounds. II

AU Vadodaria, D. J.; Deliwala, Chimanlal V.; Mandrekar, S. S.; Sheth, U. K.

CS Haffkine Inst., Bombay, India

SO J. Med. Chem. (1969), 12, 860-5

CODEN: JMCMAR

DT Journal

LA English

AB Ninety-three N1,N4-disubstituted piperazine derivatives in which the N1-substituents are 3-(p-chlorophenyl)-3-phenylpropionyl, 3-(p-chlorophenyl)-3-phenylpropyl, .omega.-(p-chloro-.alpha.-phenylbenzyloxy)alkyl, .beta.-(p-chloro-.alpha.-phenylbenzylthio)ethyl, .beta.-(p-chloro-.alpha.-phenylbenzylamino)ethyl, or .beta.-(1,2-diphenylethylamino)ethyl and the N4-substituents are Me, 2-hydroxypropyl, 2-(2-hydroxyethoxy)ethyl, cyclohexyl, benzyl, m-methyl- and p-tert-butylbenzyl, p-chloro-.alpha.-phenylbenzyl, phenethyl, Ph, chloro-, and methoxyphenyl, tolyl, 2-pyridyl, 2-pyrimidinyl, or 2-thiazolyl have been synthesized. So have some N,N'-disubstituted ethylenediamines in which the substituent is p-chloro-.alpha.-phenylbenzyl and N'-substituents are alkyl groups or N' is a part of morpholine or piperidine. Screening for central nervous system (CNS) activity revealed that some compds. possessed significant CNS depressant activity. A few compds. exhibited promising antihistaminic activity in exptl. animals.

IT 23902-92-3P 23904-73-6P 23940-99-0P

23941-00-6P 23941-10-8P 23941-11-9P

23941-12-0P 24042-30-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 23902-92-3 CAPLUS

CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(o-methoxyphenyl)-, maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 33656-14-3

CMF C26 H29 Cl N2 O




excluded.

CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.




RN 23904-73-6 CAPLUS

CM ~~Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-p-tolyl-, maleate~~
(1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 33656-17-6
CMF C26 H29 Cl N2

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 23940-99-0 CAPLUS

CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(pyrazinyl)-, maleate
(1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47581-22-6

CMF C23 H25 Cl N4




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 23941-00-6 CAPLUS


CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(2-thiazolyl)-,
maleate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 33656-19-8

CMF C22 H24 Cl N3 S






RN 23941-11-9 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-o-tolyl-, maleate
(1:1) (8CI) (CA INDEX NAME)

CM 1


CRN 33656-15-4
CMF C26 H29 Cl N2



CM 2

CRN 110-16-7
CMF C4' H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 23941-12-0 CAPLUS
CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-m-tolyl-, maleate
(1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 33656-16-5

CMF C26 H29 Cl N2




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 24042-30-6 CAPLUS

CN Piperazine, 1-[3-(p-chlorophenyl)-3-phenylpropyl]-4-(2-pyridyl)-, maleate
(1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 33656-18-7


CMF C24 H26 Cl N3



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



=> d bib abs hitstr 31

L13 ANSWER 31 OF 32 CAPLUS COPYRIGHT 1999 ACS
AN 1969:87854 CAPLUS
DN 70:87854
TI Di- and triphenylpropyl piperazine derivatives
IN Regnier, Gilbert; Canevari, Roger; Le Douarec, Jean C.
PA Science Union et Cie.-Societe Francaise de Recherche Medicale
SO S. African, 17 pp.
CODEN: SFXAB

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6801455		19680812		
PRAI	GB		19670314		

AB The title compds., useful as analgesics, antiinflammatory agents and as antitussives, are prepd. by alkylating the appropriate piperazine with a halo-substituted heterocyclic compd. Thus, a mixt. of 40 g. K₂CO₃, 15.8 g. 2-bromopyridine and 35.6 g. 1-(3,3, 3-triphenylpropyl)piperazine (m. 131.degree.) in 100 cc. HCONMe₂ was heated 7 hrs. at 150.degree. and worked up to give 25 g.


1-(3,3,3-triphenylpropyl)-4-(2-pyridyl)piperazine,
m. 148.degree.. Other compds. were cited but no details of prepn. or phys. properties were given. Some pharmacol. data are given.

IT 21801-31-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21801-31-0 CAPLUS

CN Piperazine, 1-(2-pyridinyl)-4-(3,3,3-triphenylpropyl)- (9CI) (CA INDEX NAME)



=> D

L13 32 BIB ABS HITSTR

L13 ANSWER 32 OF 32 CAPLUS COPYRIGHT 1999 ACS

AN 1969:11717 CAPLUS

DN 70:11717

TI 1-(3,3-Diphenylpropyl)-4-(2-pyrimidinyl)piperazines

IN Regnier, Gilbert; Canevari, Roger; Le Douarec, Jean C.; Laure, Michel

PA Science Union et Cie.-Societe Francaise de Recherche Medicale

SO Fr., 5 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1505109		19671208		
PRAI	GB		19651216		

GI For diagram(s), see printed CA Issue.

AB Piperazines (I) are prepd. from II (R = 3-phenylpropyl) and 2-chloropyrimidines and from II (R = 2-pyrimidyl) and Ph₂C(Ar)CH₂CH₂X compds. A mixt. of 15. g. II (R = Ph₂CHCH₂CH₂) (III) 16.4 g. 2-chloropyrimidine, 250 ml. HCONMe₂, and 27.6 g. K₂CO₃ is heated 7 hrs.

at

150.degree. to give 25 g.

1-(3,3-diphenylpropyl)-4-(2-pyrimidyl)piperazine

(IV), m. 111.degree.. Similarly prepd. are the following I (Ar, R, R₁, R₂, m.p., salt, and salt m.p. given): H, H, Cl, Cl, -, MeSO₃H, 251.degree.; H, Me, H, H, 80.degree., -, -; H, Me, Me, H, -, fumarate, 195-205.degree. (decompn.); H, Me, H, Me, 103-5.degree., -, -; H, MeO, H, H, 88.degree., -, -; H, NH₂, H, H, -, 2HCl, 164-5.degree.; H, NHMe, H, H, -, 2HCl, 175-8.degree.; H, NMe₂, H, H, -, 2HCl, 178-81.degree.; H, H, (R₁R₂ =) benzo, -, 2HCl, 235-40.degree.; Ph, H, H, H, 130.degree., -, -; Ph, H, Cl, H, 124.degree., -, -; Ph, OH, H, H, -, 2HCl.H₂O, 176-80.degree.

(decompn.); Ph, Me, H, H, 128.degree., -, -; Ph, Me, Me, H, -, fumarate, 190-200.degree. (decompn.); Ph, Me, H, Me, 140.degree., -, -; Ph, MeO, H, H, 125.degree., -, -; Ph, NH₂, H, H, - (2H₂O) 132-40.degree., -, -; Ph, NHMe, H, H, 150-3.degree., -, -; Ph, NMe₂, H, H, 115.degree., -, -; Ph, NHCH₂CH₂CH₂, H, H, 154-8.degree., -, -; Ph, H, (R₁R₂ =) benzo, -, fumarate, 195-200.degree. (decompn.). The following compds. are also

prepd. (m.p., salt, and salt m.p. given): 1-(3,3-diphenylpropyl)-4-(4-pyrimidyl)piperazine, -, fumarate monohydrate, 233-7.degree.; 1-(3,3-diphenylpropyl)-4-(4-benzopyrimidyl)piperazine, -, 2HCl, 230-5.degree.; 1-(3,3-diphenylpropyl)-4-(2-methyl-4-benzopyrimidyl)piperazine, - fumarate hemihydrate, 167-70.degree.; 1-(3,3,3-triphenylpropyl)-4-(4-pyrimidyl)piperazine, - (2H₂O 64-6.degree.), -, -; 1-(3,3,3-triphenylpropyl)-4-(2-amino-4-pyrimidyl)piperazine, 188-90.degree., -; 1-(3,3,3-triphenylpropyl)-4-(4-benzopyrimidyl)piperazine, -, 2HCl, 155-60.degree.; 1-(3,3,3-triphenylpropyl)-4-(2-methyl-4-benzopyrimidyl)piperazine, -, fumarate, 205-10.degree. (decompn.). 1-(2-Pyrimidyl)piperazine is treated with

Ph₂CHCH₂CH₂Br and p-MeC₆H₄SO₃CH₂CH₂CPh₃ to give IV and I (Ar = Ph, R = R₁ = R₂ = H), m. 130.degree., resp. III (2HCl salt m. 215-18.degree.) and

II

(R = Ph₃CCH₂CH₂) (2 MeSO₃H salt m. 184-7.degree.) are prepd. from piperazine.

IT 20974-39-4P 20974-40-7P 20974-41-8P

20974-42-9P 20980-02-3P 20980-03-4P
20980-04-5P 20980-05-6P 20980-06-7P
20980-08-9P 20980-09-0P 20980-11-4P
20980-12-5P 20980-13-6P 20980-14-7P
20980-15-8P 20980-16-9P 20980-17-0P
20980-18-1P 20980-19-2P 20980-20-5P
21026-23-3P 21026-24-4P 21026-25-5P
21026-26-6P 21026-27-7P 21162-92-5P
21178-20-1P 22307-06-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 20974-39-4 CAPLUS

CN Pyrimidine, 5-chloro-2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-,
monomethanesulfonate (8CI) (CA INDEX NAME)

CM 1

CRN 47581-42-0


CMF C23 H25 Cl N4



CM 2


CRN ~~75-73-2~~

CMF C H4 O3 S




RN 20974-40-7 CAPLUS


CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4-methyl- (8CI) (CA
INDEX NAME)



RN 20974-41-8 CAPLUS


CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4,6-dimethyl- (8CI)
(CA INDEX NAME)

RN 20974-42-9 CAPLUS

CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4-methoxy- (8CI)
(CA INDEX NAME)


RN 20980-02-3 CAPLUS

CN Pyrimidine, 4-amino-2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

RN 20980-03-4 CAPLUS
 CN Pyrimidine, 4-(dimethylamino)-2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

RN 20980-04-5 CAPLUS
 CN Quinazoline, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

RN 20980-05-6 CAPLUS

CN Quinazoline, 4-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, dihydrochloride
(8CI) (CA INDEX NAME)*excluded*CH₂-CH₂-CHPh₂

● 2 HCl

RN 20980-06-7 CAPLUS

CN Pyrimidine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA
INDEX NAME)CH₂-CH₂-CPh₃

RN 20980-08-9 CAPLUS

CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4-(methylamino)-,
dihydrochloride (8CI) (CA INDEX NAME)

=> d an hitstr 4


L14 ANSWER 4 OF 4 COPYRIGHT 1999 ACS

AN CA57:13780e CAOLD

IT 96869-60-2 98588-49-9

RN 96869-60-2 CAOLD


CN 1-Piperazinebutyramide, 4-(o-methoxyphenyl)-.alpha.,.alpha.-diphenyl-
(7CI) (CA INDEX NAME)



excluded


RN 98588-49-9 CAOLD

CN 1-Piperazinebutyronitrile, 4-(o-methoxyphenyl)-.alpha.,.alpha.-diphenyl-,
dihydrochloride (7CI) (CA INDEX NAME)




excluded

• 2 HCl




● 2 HCl

RN 20980-09-0 CAPLUS
CN Pyrimidine, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-11-4 CAPLUS
CN Pyrimidine, 4-methyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-12-5 CAPLUS
CN Pyrimidine, 4,6-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-

(8CI, 9CI) (CA INDEX NAME)




RN 20980-13-6 CAPLUS

CN Pyrimidine, 4-methoxy-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA INDEX NAME)




RN 20980-14-7 CAPLUS

CN 4-Pyrimidinamine, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 20980-15-8 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 20980-16-9 CAPLUS
CN 4-Pyrimidinamine, N-methyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)




RN 20980-17-0 CAPLUS
CN 4-Pyrimidinamine,
N,N-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)



RN 20980-18-1 CAPLUS
CN 4-Pyrimidinamine,
N-2-propenyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)




RN 20980-19-2 CAPLUS
 CN Quinazoline, 4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
 dihydrochloride
 (8CI, 9CI) (CA INDEX NAME)



● 2 HCl

RN ~~20980-20-5~~ CAPLUS
 CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]- (8CI, 9CI) (CA
 INDEX NAME)




RN 21026-23-3 CAPLUS
 CN Pyrimidine, 4-[4-(3,3-diphenylpropyl)-1-piperazinyl]-, fumarate (1:1)

(8CI) (CA INDEX NAME)

CM 1

CRN 47544-49-0

CMF C23 H26 N4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 21026-24-4 CAPLUS

CN Quinazoline, 4-[4-(3,3-diphenylpropyl)-1-piperazinyl]-2-methyl-, fumarate
(1:1) (8CI) (CA INDEX NAME)~~CM 1~~

CRN 47704-65-4

CMF C28 H30 N4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 21026-25-5 CAPLUS

CN Pyrimidine, 4,5-dimethyl-2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47758-61-2

CMF C31 H34 N4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 21026-26-6 CAPLUS

CN Quinazoline, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47787-36-0

CMF C33 H32 N4




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 21026-27-7 CAPLUS

CN Quinazoline, 2-methyl-4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 47796-32-7

CMF C34 H34 N4




CM 2

CRN 110-17-8


CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 21162-92-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 21178-20-1 CAPLUS
CN Pyrimidine, 2-[4-(3,3-diphenylpropyl)-1-piperazinyl]-4,5-dimethyl-,
fumarate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47625-97-8
CMF C25 H30 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.


HO₂C ^E CO₂H

RN 22307-06-8 CAPLUS
CN Pyrimidine, 5-chloro-4-[4-(3,3,3-triphenylpropyl)-1-piperazinyl]- (8CI)
(CA INDEX NAME)

BERNHARDT

09/127059

Page 14



=> d an hitstr


L14 ANSWER 1 OF 4 COPYRIGHT 1999 ACS

AN CA63:18021b CAOLD

IT 4082-41-1 4082-42-2 4082-43-3

RN 4082-41-1 CAOLD


CN 1-Piperazinepropanol, .beta.-methyl-.alpha.,.alpha.,4-triphenyl- (7CI, 8CI) (CA INDEX NAME)



~~12 vs 13~~
2 diffs ~~proviso~~ requires at least
one Ph's must be subst of


RN 4082-42-2 CAOLD

CN 1-Piperazinepropanol, 4-(p-methoxyphenyl)-.beta.-methyl-.alpha.,.alpha.-diphenyl- (7CI, 8CI) (CA INDEX NAME)



RN 4082-43-3 CAOLD

CN 1-Piperazinepropanol, 4-(p-chlorophenyl)-.beta.-methyl-.alpha.,.alpha.-diphenyl- (7CI, 8CI) (CA INDEX NAME)



=> d an hitstr 2


L14 ANSWER 2 OF 4 COPYRIGHT 1999 ACS

AN CA57:13780g CAOLD

IT 96269-21-5 96310-84-8 96931-47-4


RN 96269-21-5 CAOLD

CN 1-Piperazinebutanol, .alpha.-ethyl-4-(o-methoxyphenyl)-.beta.,.beta.-
diphenyl- (7CI) (CA INDEX NAME)




RN 96310-84-8 CAOLD

CN 3-Hexanone, 6-[4-(o-methoxyphenyl)-1-piperazinyl]-4,4-diphenyl- (7CI)
(CA INDEX NAME)



RN 96931-47-4 CAOLD

CN 1-Piperazinebutanol, 4-(o-methoxyphenyl)-.alpha.-methyl-.beta.,.beta.-
diphenyl- (7CI) (CA INDEX NAME)



=> d an hitstr 3

L14 ANSWER 3 OF 4 COPYRIGHT 1999 ACS

AN CA57:13780f CAOLD

IT 98878-82-1

RN 98878-82-1 CAOLD

CN 2-Pentanone, 5-[4-(o-methoxyphenyl)-1-piperazinyl]-3,3-diphenyl- (7CI)
(CA INDEX NAME)

